REPORT ID 6540

EMEA (Europe, Middle East and Africa) Axial Spondyloarthritis Drugs Market Report 2017

Publish Date
26-Dec-17
Pages
101
Format
Electronic (PDF)

In this report, the EMEA Axial Spondyloarthritis Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Axial Spondyloarthritis Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Axial Spondyloarthritis Drugs market competition by top manufacturers/players, with Axial Spondyloarthritis Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca Plc
    Eli Lilly and Company
    Johnson & Johnson
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    Sun Pharma Advanced Research Company Ltd
    UCB SA

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Certolizumab Pegol
    Etanercept Biosimilar
    Ixekizumab
    Secukinumab
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hospital
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Axial Spondyloarthritis Drugs Market Report 2017
1 Axial Spondyloarthritis Drugs Overview
    1.1 Product Overview and Scope of Axial Spondyloarthritis Drugs
    1.2 Classification of Axial Spondyloarthritis Drugs
        1.2.1 EMEA Axial Spondyloarthritis Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Axial Spondyloarthritis Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Certolizumab Pegol
        1.2.4 Etanercept Biosimilar
        1.2.5 Ixekizumab
        1.2.6 Secukinumab
        1.2.7 Others
    1.3 EMEA Axial Spondyloarthritis Drugs Market by Application/End Users
        1.3.1 EMEA Axial Spondyloarthritis Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Home Care
    1.4 EMEA Axial Spondyloarthritis Drugs Market by Region
        1.4.1 EMEA Axial Spondyloarthritis Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Axial Spondyloarthritis Drugs (2012-2022)
        1.5.1 EMEA Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Axial Spondyloarthritis Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Axial Spondyloarthritis Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Axial Spondyloarthritis Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Axial Spondyloarthritis Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Axial Spondyloarthritis Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Axial Spondyloarthritis Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Axial Spondyloarthritis Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Axial Spondyloarthritis Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Axial Spondyloarthritis Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Axial Spondyloarthritis Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Axial Spondyloarthritis Drugs (Volume) by Application
    2.4 EMEA Axial Spondyloarthritis Drugs (Volume and Value) by Region
        2.4.1 EMEA Axial Spondyloarthritis Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Axial Spondyloarthritis Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Axial Spondyloarthritis Drugs Sales Price by Region (2012-2017)

3 Europe Axial Spondyloarthritis Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Axial Spondyloarthritis Drugs Sales and Value (2012-2017)
        3.1.1 Europe Axial Spondyloarthritis Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Axial Spondyloarthritis Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Axial Spondyloarthritis Drugs Sales and Market Share by Type
    3.3 Europe Axial Spondyloarthritis Drugs Sales and Market Share by Application
    3.4 Europe Axial Spondyloarthritis Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Axial Spondyloarthritis Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Axial Spondyloarthritis Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)

4 Middle East Axial Spondyloarthritis Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Axial Spondyloarthritis Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Axial Spondyloarthritis Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Axial Spondyloarthritis Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Axial Spondyloarthritis Drugs Sales and Market Share by Type
    4.3 Middle East Axial Spondyloarthritis Drugs Sales and Market Share by Application
    4.4 Middle East Axial Spondyloarthritis Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Axial Spondyloarthritis Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Axial Spondyloarthritis Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)

5 Africa Axial Spondyloarthritis Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Axial Spondyloarthritis Drugs Sales and Value (2012-2017)
        5.1.1 Africa Axial Spondyloarthritis Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Axial Spondyloarthritis Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Axial Spondyloarthritis Drugs Sales and Market Share by Type
    5.3 Africa Axial Spondyloarthritis Drugs Sales and Market Share by Application
    5.4 Africa Axial Spondyloarthritis Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Axial Spondyloarthritis Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Axial Spondyloarthritis Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Axial Spondyloarthritis Drugs Sales and Growth Rate (2012-2017)

6 EMEA Axial Spondyloarthritis Drugs Manufacturers/Players Profiles and Sales Data
    6.1 AstraZeneca Plc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 AstraZeneca Plc Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Eli Lilly and Company
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Eli Lilly and Company Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Johnson & Johnson
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Johnson & Johnson Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Novartis AG
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Novartis AG Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Panacea Biotec Ltd
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Panacea Biotec Ltd Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Sandoz International GmbH
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Sandoz International GmbH Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Sun Pharma Advanced Research Company Ltd
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sun Pharma Advanced Research Company Ltd Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 UCB SA
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Axial Spondyloarthritis Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 UCB SA Axial Spondyloarthritis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview

7 Axial Spondyloarthritis Drugs Manufacturing Cost Analysis
    7.1 Axial Spondyloarthritis Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Axial Spondyloarthritis Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Axial Spondyloarthritis Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Axial Spondyloarthritis Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Axial Spondyloarthritis Drugs Market Forecast (2017-2022)
    11.1 EMEA Axial Spondyloarthritis Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Axial Spondyloarthritis Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Axial Spondyloarthritis Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Axial Spondyloarthritis Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Axial Spondyloarthritis Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Axial Spondyloarthritis Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Axial Spondyloarthritis Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Axial Spondyloarthritis Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Axial Spondyloarthritis Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Axial Spondyloarthritis Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer